

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following clinical trials evaluated the efficacy of ruxolitinib versus placebo for patients with myelofibrosis?
 - a. COMFORT
 - b. PERSIST-1
 - c. PERSIST-2
 - d. JAKARTA
 - e. JAKARTA-2
2. The PERSIST-1 and PERSIST-2 studies reported improved platelet stability in patients with myelofibrosis with which agent compared to best available therapy?
 - a. Ruxolitinib
 - b. Alisertib
 - c. Fedratinib
 - d. Pacritinib
3. Which of the following clinical trials led to the approval of fedratinib as front-line treatment for patients with intermediate-2 or high-risk myelofibrosis?
 - a. COMFORT
 - b. PERSIST-1
 - c. PERSIST-2
 - d. JAKARTA
 - e. JAKARTA-2
4. Which of the following drug types best describes the mechanism of action of momelotinib?
 - a. PI3K inhibitor
 - b. Antibody-drug conjugate
 - c. JAK inhibitor
 - d. PARP inhibitor